# Magnetic Nanocarriers with ICPTES- and GPTMS-Functionalized Quaternary Chitosan for pH-Responsive Doxorubicin Release

## TL;DR

Researchers developed magnetic nanocarriers that release chemotherapy drugs in acidic tumor environments, improving drug delivery and cancer cell targeting.

## Contribution

Novel pH-responsive magnetic nanocarriers using quaternary chitosan for efficient and controlled doxorubicin release in cancer treatment.

## Key findings

- Nanocarriers achieved 90% doxorubicin loading efficiency and pH-dependent release in acidic tumor-like conditions.
- MNP-HTCC1 showed stronger cytotoxicity against breast cancer cells compared to free doxorubicin.
- Drug release followed a diffusion-controlled mechanism, consistent with Fickian transport through the nanocarrier matrix.

## Abstract

Smart nanocarriers are being increasingly explored to improve the performance selectivity of cancer chemotherapy. Here, two pH-responsive magnetic nanocarriers were developed using quaternary chitosan (HTCC) functionalized with 3-(triethoxysilyl)propyl isocyanate- ICPTES (MNP-HTCC1) or 3-(glycidyloxypropyl)trimethoxysilane-GPTMS (MNP-HTCC2) to form hybrid silica shells on Fe3O4 cores. The resulting core–shell nanoparticles (14.5 and 12.5 nm) displayed highly positive zeta potentials (+45.4 to +27.1 mV, pH 4.2–9.5), confirming successful HTCC incorporation and strong colloidal stability. Both nanocarriers achieved high doxorubicin (DOX) loading at pH 9.5, reaching 90% efficiency and a capacity of 154 µg DOX per mg. DOX release was pH-dependent, with faster release under acidic conditions relevant to tumor and endo-lysosomal environments. At pH 4.2, MNP-HTCC1 released 90% of DOX over 72 h, while MNP-HTCC2 released 79%. Release at pH 5.0 was intermediate (67–72%), and moderate at physiological pH (43–55%). All formulations showed an initial burst followed by sustained release. Kinetic modelling (Weibull) indicated a diffusion-controlled mechanism consistent with Fickian transport through the HTCC–silica matrix. Cytotoxicity assays using MCF-7 breast cancer cells revealed greater cytotoxicity for DOX-loaded nanocarriers compared with free DOX, with MNP-HTCC1 showing the strongest effect. Overall, these HTCC-based magnetic nanocarriers offer efficient loading, controlled pH-triggered DOX release, and enhanced therapeutic performance.